This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Biomarkers Market

Biomarkers Market

Biomarkers Market Analysis by Disease Type (Cardiovascular Diseases, Cancer, Neurological Diseases, Immunological Diseases), by Type (Safety, Efficacy, Validation Biomarkers), by Application & by Region - Global Forecast 2022-2032

Biomarkers Market
  • Mar-2022
  • List of Tables : 72
  • List of Figures : 148
  • 170 Pages
  • Healthcare

Biomarkers Market Outlook

The global sales of Biomarkers in 2021 was held at US$ 59.1 Bn. With 15.3%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Safety Biomarkers are expected to be the highest revenue generating biomarker type, with a projected growth of 15.9% during 2022 – 2032.

Key Points Covered in Biomarkers Industry Survey:

  • Market Estimates and Forecasts (2017-2032)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis
  • COVID-19 Impact on Biomarkers and How to Navigate
  • Recommendation on Key Winning Strategies

Avail customized purchase options for your needs

Revenue of Biomarkers from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the Biomarkers industry research by Fact.MR - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Biomarkers industry increased at around 13.6% CAGR, wherein, countries such as the Germany, U.S., China and Japan held significant share in the global market.

The constant surge in urbanization is propelling the demand for various commodities which is consequently driving the need for logistics. Owing to this, Biomarkers market is projected to grow at a CAGR of 15.3% over the coming 10 years.

  • The Biomarkers market reached a valuation of US$ 59.1 Bn in 2021. Fact.MR estimates that Biomarkers revenue will grow 4.1X from 2022 to 2032, reaching nearly US$ 278 Bn in 2032.
  • Safety Biomarkers are held the largest share in the market of 38%.
  • Japan is expected to be the fastest growing market for Biomarkers, with a CAGR of 17.2%.
  • Cancer detection show the highest potential for growth in the Biomarkers industry in the disease type segment. It is expected to grow at a rate of about 17.1% during the next ten years.

What Factors are leading to Growth of the Biomarkers industry?

There are several hurdles associated with drug development, where the key restraint is its failure rate. Even drugs that have undergone all types of animal testing and all other types of testing through the entire preclinical process may have less than a tenth chance of actually hitting the market once they reach humans. Around 9 out of 10 people can fail during this development. Biomarkers help in several ways including accelerating the availability of treatment, as well as lowering the cost of drug development.

Biomarkers are characteristics of the body that one can measure. Biomarkers are very critical to medicine in general. People are used to visiting the doctors and getting test results of Xray results or CT scans. Biomarkers that tell how the body is doing, and they are measurable. Biomarkers are an integral part of drug research and development processes; they are required, as the tests have to assess the effectiveness of medicines on human beings during clinical investigation.

An Adaptive Approach to Modern-day Research Needs

How Biomarkers are Being Effectively used for Diagnostics?

The diagnostic biomarker market has found that breakthroughs in diagnostic tools provide accurate and consistent results in early diagnosis compared to traditional diagnostic tools. Biomarkers are integrated with advanced data management technology and key imaging. Therefore, it meets the needs of early detection and meets the expectations of the market.

Medical practice requires an accurate diagnosis of illness or conditions. Diagnostic biomarkers critically determine whether a patient has a particular medical condition that may require treatment, or whether an individual needs to be enrolled in a clinical trial investigating a particular disease. As is increasingly recognized, many diseases have subtypes that have significantly different prognosis or response to a particular treatment.

Diagnostic biomarkers are used only in symptomatic patients, as opposed to screening biomarkers, which are only applicable to symptomatic individuals. Interestingly, the properties of ideal diagnostic biomarkers are similar to those of screening. In particular, the most established biomarkers for screening can be used as diagnostic markers. Currently available cancer biomarkers are still less diagnostically sensitive and specific with respect to the limitations encountered with diagnostic biomarkers. However, diagnostic biomarkers must be sensitive in order to be good diagnostic biomarkers.

Which Region is projected to Offer the Largest Opportunity for Biomarkers?

Biomarkers market is expected to grow at a substantial rate in the forthcoming years. The market in Asia is expected to register the highest CAGR of during the forecast period due to increased demand for Biomarkers in developing countries, especially Japan and China. This increase is also due to the growing awareness among various consumers.

A large share of the region is because of the increasing use of biomarkers in personalized medicine, the various growth strategies of major companies with well-established pharmaceutical companies, and the acceptance of biomarkers primarily for disease diagnosis in cancer diagnosis.

Interested to Procure The Data

Country-wise Analysis

Which Country Topped the Revenue Generation for Biomarkers Market?

The U.S. dominated the market in 2021 with a market share of over 55%. This is due to increased R & D investment and the local presence of global players.

Over the last decade, the number of USFDA-approved drug labels containing molecular biomarker information has increased significantly. In addition, almost all pharmaceutical companies have developed molecular biomarker programs through partnerships or other ventures. Molecular biomarkers are identified and validated in drug development and used to support drug approval. Approval of such drugs has helped grow the U.S. kidney biomarker market. The American Cancer Society reports that 609,640 people have died of cancer in the country. In 2018, 234,030 cases of lung cancer occurred in the United States, and 154,050 people died of lung cancer.

Category-wise Insights

What makes the Safety Biomarkers Largest Revenue Generator in Biomarkers Market?

Safety Biomarkers held the largest share of sales in 2021 with more than 38.0%. It is expected to grow at a CAGR of 15.9% in the next ten years. Recent developments in the Biomarkers market such as Biomarker signatures are enabling various neurological diseases more treatable by the day.

Increasing use of biomarkers for the treatment of multiple infectious diseases is making a significant impact on the demand for biomarkers, which is expected to be continued in the coming years as well. The market for Safety Biomarkers is driven by a high awareness of regular health checks, a low rate of drug consumption, and an increase in the population at high risk of developing various diseases such as cancer, cardiovascular disease and kidney disorders.

Which Disease Type shows the Highest Potential over the Next Ten Years for Biomarkers Market?

Cancer detection show the highest potential for growth in the biomarkers industry in the disease type segment. It is expected to grow at a rate of about 17.1% during the next ten years.

Around 25 years ago, the clinical utility of Cancer Biomarkers was limited to effective tools for patient prognosis, monitoring, and treatment monitoring. Cancer biomarkers is released from tumor cells or somatic cells in response to the tumor and can be detected in fluids, secretions, or tumor tissues or cells. Cancer biomarkers can be detected in serum, plasma, or whole blood, as well as in whole excrement such as urine, sputum, or CSF.

Therefore, Cancer biomarkers can be evaluated non-invasively and continuously. Evaluating tissue or cell cancer biomarkers requires more invasive techniques than tissue biopsies or serum biomarkers. Cancer biomarkers can be detected in tissues by special techniques, but invasively as a biomarker of serum or urine. Genetic biomarkers can be detected in DNA from tumor tissue, whole blood, or buccal mucosal cells. Therefore, it can be said that biomarkers are expected to continue being the important in the detection of cancer at various stages and helping in its prevention altogether.

How Has COVID-19 Impacted Revenue Generation from Biomarkers?

The impact of COVID-19 on Biomarkers was not much seen in biomarkers market. Despite the heavy blows to almost all the industries, the Biomarkers industry generated a revenue of US$ 59 Bn in 2021 and continued to grow positively at a rate of 14% over the last year. The reason for the growth of the industry during the pandemic may be credited to the growing health concern of the customers during the pandemic.

Competitive Analysis

The key players such as F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc. adopt several organic and inorganic strategies to enhance their revenue and market standings.

Some of the recent developments of key Biomarkers providers are as follows:

  • In May, 2021, Cerascreen KRAS RGQ PCR Kit, the first FDA-approved diagnostic tissue specimen to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer, was launched.
  • In April, 2021, F. Hoffmann La Roche Ltd. launched two cardiac biomarker tests, the Sensitive Cardiac Troponin T (cTnThs) and the N-Terminal Pro Brain Sodium Diuretic Peptide Test (NTproBNP). These gold standard biomarkers support the management of cardiovascular disease and may help physicians diagnose heart attacks and better manage heart failure.
  • In July 2020, Thermo Fisher Scientific has signed an agreement with Chugai to expand the use of oncomin Dx targeted tests in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker tests.
  • In January 2020, in partnership with the Institute for Microbial Technology (CSIRIMTECH), Merck KGaA opened a research institute in Chandigarh, India, with a focus on genome editing, biomarker detection, and life sciences. The facility is equipped with cutting-edge technology needed for on-site students.

Similarly, recent developments related to companies offering Biomarkers have been tracked by the team at Fact.MR, which are available in the full report.

Biomarkers Market Report Scope



Forecast Period


Historical Data Available for


Market Analysis

US$ Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • MEA

Key Countries Covered

  • U.S.
  • U.K.
  • China
  • Japan
  • South Korea
  • Germany
  • France
  • Italy
  • Spain
  • Brazil
  • Mexico
  • Argentina
  • South Africa
  • Saudi Arabia
  • UAE
  • Australia
  • India

Key Market Segments Covered

  • Disease
  • Application
  • Region

Key Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Epigenetics AG
  • General Electric
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Qiagen


Available upon Request

Market Segments Covered in Biomarkers Industry Analysis

  • By Disease Type :

    • Cardiovascular Diseases
    • Cancer
    • Neurological Diseases
    • Immunological Diseases
    • Other Disease Types
  • By Type :

    • Safety
    • Efficacy
    • Validation
  • By Application :

    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicines
    • Other Applications

- FAQs -

The global Biomarkers market is worth more than US$ 67.6 Bn at present.
Value of Biomarkers are projected to increase at a CAGR of around 15.3% during 2022 – 2032.
Value of Biomarkers increased at a CAGR of around 13.6% during 2017 – 2021.
The main factors driving the growth of the Biomarkers market include an increase in patients suffering from severe diseases, the emergence of technologically advanced treatment procedures and devices, and increasing demand for various sort of Biomarkers.
Top 5 countries driving demand for Biomarkers are U.S., U.K., China, Japan and South Korea.
North America accounted for over 14% of global Biomarkers demand in 2021.
The European market for Biomarkers is projected to expand at a CAGR of around 13% during 2022 – 2032.

Need an Exclusive Report for your Unique Requirement?

- Related Reports -

Pelvic Floor Electrical Stimulation Devices Market

Global pelvic floor electrical stimulation devices market size will expand at over 9% CAGR from 2020...

Biological Derived Devices Market

Biological Derived Devices Market research report covers detailed information on Global Biological D...

Neurorehabilitation Devices Market

Worldwide demand for neurorehabilitation devices is expected to rise at a prolific CAGR of 15% to re...

Induced Pluripotent Stem Cell (iPSC) Market

Induced Pluripotent Stem Cell (iPSC) Market is projected to reach a valuation of US$ 2.3 Bn by 2026....

- Our Clients -

Report Client